Advanced Lung Cancer Clinical Trial
Official title:
Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Lung Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced lung cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for lung cancer.
Primary pulmonary carcinoma is one of the most common malignancies in China, ranking first in all malignant tumors and mortality.Immunetherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced lung cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy，and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy. The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04575831 -
Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)
|
N/A | |
| Completed |
NCT04069494 -
Descriptors and Predictors of Burden and Information Needs
|
||
| Terminated |
NCT03330834 -
CAR-T Cell Immunotherapy for Advanced Lung Cancer
|
Phase 1 | |
| Withdrawn |
NCT03004105 -
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Not yet recruiting |
NCT05279521 -
The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.
|
N/A | |
| Terminated |
NCT02768337 -
Cambridge Brain Mets Trial 1
|
Phase 1/Phase 2 | |
| Completed |
NCT04672369 -
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
|
Phase 1 | |
| Recruiting |
NCT03751592 -
Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05431569 -
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06456138 -
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06228209 -
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
|
N/A | |
| Completed |
NCT04672356 -
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Not yet recruiting |
NCT06107894 -
TIL Therapy for Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06183762 -
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
|
||
| Recruiting |
NCT05664971 -
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05815862 -
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06106152 -
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
|
Early Phase 1 | |
| Recruiting |
NCT05000684 -
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
|
Phase 1/Phase 2 |